# OnCo record paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024" ;
  schema:name "GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma"@en ;
  schema:description "A new regimen built around brentuximab vedotin cured more patients with advanced Hodgkin lymphoma than the intensive BEACOPP standard, and did so with less toxicity, including less damage to fertility."@en ;
  schema:url <https://onco.cc/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(24)01315-1>, <https://pubmed.ncbi.nlm.nih.gov/38971175/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(24)01315-1> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Borchmann P, Ferdinandus J, Schneider G, et al." ;
  onco:cancers <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cyclophosphamide/> ;
  onco:trials <https://onco.cc/trials/hd21/> ;
  onco:journals <https://onco.cc/journals/lancet/> .